ClinicalTrials.gg
RecruitingNCT06967961DP-PAN-CANCERUpdated Jun 15, 2026

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

An interventional study of For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: in Urothelial Carcinoma, Renal Cancer and Prostate Adenocarcinoma, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Carcinoma, Transitional Cell with a site in France — 16 open to participants now, 28 under way, 7 of them phase 3. Carcinoma, Transitional Cell · France.

Planned enrollment
15th of 62
450 · median 181
Started
2025
with 7 others
No phase
Only one
of the 71
Primary completion
2029-07
later than 24 of 27 live
Registered
64th of 71
by date

Among the 71 studies in Carcinoma, Transitional Cell with a site in France, this one is the 15th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2025, is the only one with no phase, reaches primary completion later than 24 of the 27 other live ones, and was the 64th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

16 of the 71 studies in Carcinoma, Transitional Cell with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Transitional Cell with a site in France, or all of them as a file.
02

Study summary

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.

Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.

450 patients will be enrolled in total.

03

Conditions studied

  • Urothelial Carcinoma
  • Renal Cancer
  • Prostate Adenocarcinoma
  • Adenocarcinoma of Endometrium
  • Cutaneous Melanoma
  • Soft Tissue Sarcoma (STS)
  • Nonseminomatous Germ Cell Tumor
  • Seminomatous Germ Cell Tumor
  • Upper Aerodigestive Tract Carcinoma
  • Cervical Carcinoma

Keywords

  • metastatic cancers
  • Double Positive Circulating cells
  • liquid biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
  • 2. disease for which the treatment (whatever the line) has not been initiated yet
  • 3. Age ≥ 18 years
  • 4. Patient affiliated to a French Social Security scheme
  • 5. Patient having signed his/her prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

Exclusion Criteria:

  • 1. Patient with localized disease.
  • 2. Pregnant or breast-feeding women.
  • 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
  • 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Other
    Patients with metastatic cancer

    * Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients: * Cohort 1 : urothelial carcinoma * Cohort 2 : renal carcinoma * Cohort 3 : prostate adenocarcinoma * Cohort 4 : upper aerodigestive tract carcinoma * Cohort 5 : cervical carcinoma * Cohort 6 : adenocarcinoma of endometrium * Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients: * Cohort 7 : cutaneous melanoma * Cohort 8 : soft tissue sarcoma * Cohort 9 : seminomatous and nonseminomatous germ cell tumors

    Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

Interventions

  • OtherFor each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

    A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

06

What researchers measure

Primary outcomes

  1. Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor)

    It is defined as the ratio of number of patients for whom DP cells were detected (by at least 1 of the 2 techniques) by the total number of patients.

    Time frame: 1 year after the Last Patient Last Visit

Secondary outcomes

  1. Rate of patients presenting blood circulating DP cells detected by each method of analysis (Flow Cytometry and CellSearch® or Parsortix® according to the tumor type)

    It is defined as the ratio of the number of patients presenting DP cells (detected by the concerned technique) by the total number of patients

    Time frame: 1 year after the Last Patient Last Visit

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.

Of 29 interventional studies with no phase under Carcinoma, Transitional Cell, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 23. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 13, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Jul 23, 2029
CompletionEst.
Jul 23, 2029
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06967961
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Jul 23, 2025
Primary completion
Jul 23, 2029 (estimated)
Completion
Jul 23, 2029 (estimated)
Last update
Jun 15, 2026

Study contacts

Thibaud VALENTIN, MD
Contact
valentin.thibaud@iuct-oncopole.fr
0033 5 31 15 51 70

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion